Re: NARHEX AUSTRALIA PTY LIMITED
And: SUNSPOT PRODUCTS PTY LIMITED and WARWICK JOHN PLUNKETT
No. G882 of 1989
FED No. 412
COURT
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
Foster J.(1)
HEARING
SYDNEY
#DATE 14:8:1990
ORDER
(A) as to the application:
(1) that the respondents, by themselves, their servants or agents or otherwise, be restrained from representing that any product manufactured or marketed by or on behalf of either of them which contains cross-linked elastin contains:
(i) 10% cross-linked elastin,
(ii) approximately 1mg per ml of active elastin,
(iii) 10% of cross-linked elastin CLR solution.
(2) that the respondents by themselves, their servants or agents or otherwise, be restrained from representing that any product manufactured or marketed by or on behalf of either of them contains any proportion of cross-linked elastin except by stating the specific percentage of cross-linked elastin contained in the product as a whole.
(3) that the operations of orders 1 and 2 shall be stayed until 1 September 1990.
(4) that liberty to be reserved in respect of order 2 should the appellant cease to market its cross-linked 10/60 elastin products.
(B) as to the cross-claim:
(1) that the applicant shall not by itself, its servants or agents or otherwise, whether by way of dissemination, preparation, distribution or autherisation of advertising (whether by way of print or electronic media) packaging, promotional, instructional or distributional literature associated with or relating to the product known as "Cross-linked 10/60 Elastin" or "Narhex Cross-linked 10/60 Elastin" represent that the applicant is French and/or its product is manufactured in, distributed in, and/or distributed from France and/or Paris, or has some other connection with France or Paris.
(2) in relation to the applicant's stock of packaged products referred to in the affidavit of J.W. Majewski of 7 August 1990, it shall be deemed sufficient compliance with the above order if each package is over-labelled on a side panel with a sticker containing the statement "This product is not made or distributed in France", such overlabelling to be effected on or before 18 September 1990.
(3) in relation to the advertisements referred to in the affidavit of J.W. Majewski of 7 August 1990, it shall be deemed sufficient compliance with the above order if, in respect of each advertisement, commencing with the advertisement arranged for 18 August 1990 there be,
(a) a deletion of the word "Paris" and
(b) the insertion, in a clear and prominent manner of the statement "these products are not manufactured, distributed or marketed in France and have no other connection with that country".
(4) in respect of all other advertising to be undertaken by or on behalf of the applicant up to and including 31 December 1990 the same steps shall be taken, if necessary, as set out in orders (3) (a) and (b).
(5) liberty is reserved to apply on one day's notice in respect of the implementation of these orders.
Futher as to the cross-claim.
It is noted that the…
Keep reading for free
Create a free CaseChat account to read Narhex Australia Pty Ltd v Sunspot Products Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [1990] FCA 412
- Decision Date
CaseChat Overview and Summary
The court's reasoning was based on the Trade Practices Act, which prohibits misleading or deceptive conduct in trade or commerce. The court found that the respondent's claims were misleading because they overstated the concentration of cross-linked elastin in their products and falsely implied that their products were connected to France. The court also found that the applicant's claims were misleading because they implied that they were the only ones who developed and marketed kappa elastin. The court noted that the representations made by both parties were likely to mislead reasonable consumers, and that this was a significant factor in their decision. The court also considered the potential harm to both parties and the public interest in preventing misleading conduct. The court's outcome was that the respondent was restrained from making false claims about their products and the applicant was required to correct their own misleading claims. The court also made orders regarding the implementation of these injunctions.
Orders
Orders of the court
(A) as to the application:
(1) that the respondents, by themselves, their servants or agents or otherwise, be restrained from representing that any product manufactured or marketed by or on behalf of either of them which contains cross-linked elastin contains:
(i) 10% cross-linked elastin,
(ii) approximately 1mg per ml of active elastin,
(iii) 10% of cross-linked elastin CLR solution.
(2) that the respondents by themselves, their servants or agents or otherwise, be restrained from representing that any product manufactured or marketed by or on behalf of either of them contains any proportion of cross-linked elastin except by stating the specific percentage of cross-linked elastin contained in the product as a whole.
(3) that the operations of orders 1 and 2 shall be stayed until 1 September 1990.
(4) that liberty to be reserved in respect of order 2 should the appellant cease to market its cross-linked 10/60 elastin products.
(B) as to the cross-claim:
(1) that the applicant shall not by itself, its servants or agents or otherwise, whether by way of dissemination, preparation, distribution or autherisation of advertising (whether by way of print or electronic media) packaging, promotional, instructional or distributional literature associated with or relating to the product known as "Cross-linked 10/60 Elastin" or "Narhex Cross-linked 10/60 Elastin" represent that the applicant is French and/or its product is manufactured in, distributed in, and/or distributed from France and/or Paris, or has some other connection with France or Paris.
(2) in relation to the applicant's stock of packaged products referred to in the affidavit of J.W. Majewski of 7 August 1990, it shall be deemed sufficient compliance with the above order if each package is over-labelled on a side panel with a sticker containing the statement "This product is not made or distributed in France", such overlabelling to be effected on or before 18 September 1990.
(3) in relation to the advertisements referred to in the affidavit of J.W. Majewski of 7 August 1990, it shall be deemed sufficient compliance with the above order if, in respect of each advertisement, commencing with the advertisement arranged for 18 August 1990 there be,
(a) a deletion of the word "Paris" and
(b) the insertion, in a clear and prominent manner of the statement "these products are not manufactured, distributed or marketed in France and have no other connection with that country".
(4) in respect of all other advertising to be undertaken by or on behalf of the applicant up to and including 31 December 1990 the same steps shall be taken, if necessary, as set out in orders (3) (a) and (b).
(5) liberty is reserved to apply on one day's notice in respect of the implementation of these orders.
Futher as to the cross-claim.
It is noted that the applicant gives the following undertakings to the court:-
The applicant will not, by itself, its servants or agents or otherwise, represent that:
(a) the applicant developed or was partly responsible for developing a product called kappa elastin,
(b) kappa elastin is made or markated only by the applicant,
(c) only the applicant's Cross-linked 10/60 Elastin, being the range of products marketed under that name, contains cross-linked elastin.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.